Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ANDREAS SCHMID

Allopathic & Osteopathic Physicians Internal Medicine Pulmonary Disease

NPI
1962663377
CMS profile
761022
Location
KANSAS CITY, KS

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$1,117.56

9 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

Nature of paymentAmountRecords
Travel and Lodging $914.29 5
Food and Beverage $203.27 4

By paying entity

PY2023 · entire year · sorted by reported total

Paying entityAmountRecords
AstraZeneca UK Limited $1,117.56 9

Page 1 of 1; records 1–9 of 9 matching records. This page contains 9 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ANDREAS SCHMID

NPI 1962663377 · CMS profile ID 761022

Allopathic & Osteopathic Physicians / Internal Medicine / Pulmonary Disease

KANSAS CITY, KS

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–9 of 9 matching records. This page contains 9 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1962663377?year=2023&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ANDREAS SCHMID, NPI 1962663377, CMS profile ID 761022. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–9 of 9 matching records. This page contains 9 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1962663377?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). ANDREAS SCHMID, NPI 1962663377, CMS profile ID 761022. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–9 of 9 matching records. This page contains 9 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1962663377?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
ANDREAS SCHMID, NPI 1962663377, CMS profile ID 761022, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–9 of 9 matching records. This page contains 9 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1962663377?year=2023&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

9 matching records · $1,117.56 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 9 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–9 of 9.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
AstraZeneca UK Limited $153.3302/09/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1016979821 CMS
AstraZeneca UK Limited $214.5202/09/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1016998299 CMS
AstraZeneca UK Limited $23.0302/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1017006753 CMS
AstraZeneca UK Limited $52.8302/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1017046069 CMS
AstraZeneca UK Limited $82.7102/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1017087729 CMS
AstraZeneca UK Limited $214.5202/08/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1016985945 CMS
AstraZeneca UK Limited $176.9202/08/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1017056765 CMS
AstraZeneca UK Limited $44.7002/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1017079035 CMS
AstraZeneca UK Limited $155.0002/06/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1017082867 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $17,930.13 21
PY2020 $7,244.44 9
PY2023 $1,117.56 9
PY2024 $15.37 1
PY2025 $72.62 4

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2023, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2020 , PY2023 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $1,654.12 9
PY2025 Principal investigator $330,468.44 168
PY2024 Principal investigator $383,470.04 191
PY2023 Principal investigator $688,078.36 235
PY2022 Principal investigator $419,549.56 143
PY2021 Principal investigator $95,534.58 57
PY2019 Principal investigator $7,217.27 3

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

191 records in PY2024

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Insmed, Inc. $1,386.53 12/16/2024 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1067593162
Principal investigator 1 Insmed, Inc. $100.00 12/16/2024 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1067598520
Principal investigator 1 Insmed, Inc. $200.00 12/16/2024 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1067598522
Principal investigator 1 Insmed, Inc. $2,002.90 12/16/2024 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1067598524
Principal investigator 1 Insmed, Inc. $100.00 12/16/2024 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1067603892
Principal investigator 1 Insmed, Inc. $1,973.47 12/16/2024 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1067603894
Principal investigator 1 Insmed, Inc. $1,563.75 12/16/2024 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1067603896
Principal investigator 1 Insmed, Inc. $2,189.74 12/16/2024 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1067609318
Principal investigator 1 Insmed, Inc. $1.38 11/27/2024 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1067609326
Principal investigator 1 Insmed, Inc. $0.66 11/25/2024 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1067593164
Principal investigator 1 Insmed, Inc. $0.92 11/25/2024 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1067598532
Principal investigator 1 Insmed, Inc. $19,135.65 11/25/2024 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1067609324
Principal investigator 1 Insmed, Inc. $1.38 11/21/2024 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1067598526
Principal investigator 1 Insmed, Inc. $1.38 11/20/2024 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1067598528
Principal investigator 1 Insmed, Inc. $1.11 11/20/2024 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1067603898
Principal investigator 1 Insmed, Inc. $30,617.04 11/20/2024 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1067609320
Principal investigator 1 Insmed, Inc. $0.44 11/14/2024 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1067598530
Principal investigator 1 Insmed, Inc. $0.46 11/14/2024 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1067603900
Principal investigator 1 Insmed, Inc. $11,481.39 11/14/2024 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1067609322
Principal investigator 1 AstraZeneca UK Limited $6,592.50 11/13/2024 Non-covered Recipient Entity
UNIVERSITY OF KANSAS - PULMONARY
A Randomized, Double-Blind, Two-way Crossover Study to Assess the Effect of Hydrofluoroolefin (HFO) Propellant Metered Dose Inhaler (MDI) on Mucociliary Clearance Compared with Hydrofluoroalkane (HFA) Propellant MDI in Healthy Participants No dispute reported 06/30/2026 1110844212
Principal investigator 1 Insmed, Inc. $0.92 11/12/2024 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1067598534
Principal investigator 1 Insmed, Inc. $358.05 09/30/2024 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1067598518
Principal investigator 1 Insmed, Inc. $358.05 09/30/2024 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1067603888
Principal investigator 1 Insmed, Inc. $2,403.00 09/30/2024 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1067603890
Principal investigator 1 Insmed, Inc. $1,425.58 09/30/2024 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1067609314
Principal investigator 1 Insmed, Inc. $144.18 09/30/2024 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1067609316
Principal investigator 1 Insmed, Inc. $0.46 09/20/2024 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1067593108
Principal investigator 1 Insmed, Inc. $0.88 09/20/2024 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1067598474
Principal investigator 1 Insmed, Inc. $0.46 09/20/2024 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1067598484
Principal investigator 1 Insmed, Inc. $0.44 08/23/2024 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1067593082
Principal investigator 1 Insmed, Inc. $0.46 08/23/2024 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1067609270
Principal investigator 1 AstraZeneca UK Limited $64.39 08/21/2024 Non-covered Recipient Entity
UNIVERSITY OF KANSAS MEDICAL CENTER CYSTIC FIBROSIS PROGRAM
A Randomized, Double-Blind, Two-way Crossover Study to Assess the Effect of Hydrofluoroolefin (HFO) Propellant Metered Dose Inhaler (MDI) on Mucociliary Clearance Compared with Hydrofluoroalkane (HFA) Propellant MDI in Healthy Participants No dispute reported 06/30/2026 1110847373
Principal investigator 1 Insmed, Inc. $33.38 07/26/2024 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 1067590070
Principal investigator 1 Insmed, Inc. $33.38 07/26/2024 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 1067590072
Principal investigator 1 Insmed, Inc. $33.37 07/26/2024 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 1067590074
Principal investigator 1 Insmed, Inc. $93.45 07/26/2024 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 1067590076
Principal investigator 1 Insmed, Inc. $33.37 07/26/2024 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 1067590078
Principal investigator 1 Insmed, Inc. $33.38 07/26/2024 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 1067590080
Principal investigator 1 Insmed, Inc. $745.00 07/26/2024 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 1067590082
Principal investigator 1 Insmed, Inc. $33.37 07/26/2024 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 1067590084
Principal investigator 1 Insmed, Inc. $1,000.00 07/26/2024 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 1067590086
Principal investigator 1 Insmed, Inc. $53.40 07/26/2024 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1067593072
Principal investigator 1 Insmed, Inc. $400.00 07/26/2024 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1067593074
Principal investigator 1 Insmed, Inc. $400.00 07/26/2024 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1067593076
Principal investigator 1 Insmed, Inc. $33.37 07/26/2024 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 1067595584
Principal investigator 1 Insmed, Inc. $33.38 07/26/2024 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 1067595586
Principal investigator 1 Insmed, Inc. $93.45 07/26/2024 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 1067595588
Principal investigator 1 Insmed, Inc. $33.38 07/26/2024 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 1067595590
Principal investigator 1 Insmed, Inc. $33.37 07/26/2024 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 1067595592
Principal investigator 1 Insmed, Inc. $93.45 07/26/2024 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 1067595594
Principal investigator 1 Insmed, Inc. $93.45 07/26/2024 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 1067600966
Principal investigator 1 Insmed, Inc. $93.45 07/26/2024 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 1067600968
Principal investigator 1 Insmed, Inc. $33.38 07/26/2024 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 1067600970
Principal investigator 1 Insmed, Inc. $93.45 07/26/2024 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 1067600972
Principal investigator 1 Insmed, Inc. $93.45 07/26/2024 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 1067600974
Principal investigator 1 Insmed, Inc. $93.45 07/26/2024 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 1067606322
Principal investigator 1 Insmed, Inc. $93.45 07/26/2024 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 1067606324
Principal investigator 1 Insmed, Inc. $400.00 07/26/2024 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 1067606326
Principal investigator 1 Insmed, Inc. $93.45 07/26/2024 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 1067606328
Principal investigator 1 Insmed, Inc. $33.38 07/26/2024 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 1067606330
Principal investigator 1 Insmed, Inc. $665.00 07/26/2024 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 1067606332
Principal investigator 1 Insmed, Inc. $154.86 07/26/2024 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1067609258
Principal investigator 1 Insmed, Inc. $1.84 07/15/2024 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1067598486
Principal investigator 1 Insmed, Inc. $19,135.65 07/12/2024 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1067593080
Principal investigator 1 Insmed, Inc. $1,407.55 07/04/2024 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1067593078
Principal investigator 1 Insmed, Inc. $665.00 07/04/2024 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1067593160
Principal investigator 1 Insmed, Inc. $1,563.75 07/04/2024 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1067603824
Principal investigator 1 Insmed, Inc. $2,189.74 07/04/2024 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1067609260
Principal investigator 1 Insmed, Inc. $665.00 07/04/2024 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1067609312
Principal investigator 1 Insmed, Inc. $1.38 06/28/2024 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1067593084
Principal investigator 1 Insmed, Inc. $0.46 06/28/2024 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1067593090
Principal investigator 1 Insmed, Inc. $2.53 06/28/2024 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1067593092
Principal investigator 1 Insmed, Inc. $19,135.65 06/28/2024 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1067603828
Principal investigator 1 Insmed, Inc. $665.00 05/27/2024 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 1067590068
Principal investigator 1 Insmed, Inc. $53.40 05/27/2024 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1067593094
Principal investigator 1 Insmed, Inc. $154.86 05/27/2024 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1067593096
Principal investigator 1 Insmed, Inc. $154.86 05/27/2024 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1067593098
Principal investigator 1 Insmed, Inc. $400.00 05/27/2024 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1067598480
Principal investigator 1 Insmed, Inc. $133.50 05/27/2024 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1067598482
Principal investigator 1 Insmed, Inc. $444.56 05/27/2024 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1067603832
Principal investigator 1 Insmed, Inc. $600.00 05/27/2024 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1067603834
Principal investigator 1 Insmed, Inc. $133.50 05/27/2024 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1067603836
Principal investigator 1 Insmed, Inc. $400.00 05/27/2024 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 1067606320
Principal investigator 1 Insmed, Inc. $154.86 05/27/2024 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1067609266
Principal investigator 1 Insmed, Inc. $0.92 04/29/2024 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1067593088
Principal investigator 1 Insmed, Inc. $1.11 04/29/2024 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1067598476
Principal investigator 1 Insmed, Inc. $3.80 04/29/2024 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1067598478
Principal investigator 1 Insmed, Inc. $30,617.04 04/29/2024 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1067609262
Principal investigator 1 Insmed, Inc. $75.00 04/26/2024 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1067593114
Principal investigator 1 Insmed, Inc. $75.00 04/26/2024 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1067593116
Principal investigator 1 Insmed, Inc. $75.00 04/26/2024 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1067593118
Principal investigator 1 Insmed, Inc. $1,973.47 04/26/2024 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1067593140
Principal investigator 1 Insmed, Inc. $1,407.55 04/26/2024 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1067593142
Principal investigator 1 Insmed, Inc. $1,407.55 04/26/2024 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1067593144
Principal investigator 1 Insmed, Inc. $1,407.55 04/26/2024 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1067593146
Principal investigator 1 Insmed, Inc. $1,965.36 04/26/2024 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1067593148
Principal investigator 1 Insmed, Inc. $400.10 04/26/2024 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1067593150
Principal investigator 1 Insmed, Inc. $75.00 04/26/2024 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1067598500
Principal investigator 1 Insmed, Inc. $600.00 04/26/2024 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1067603830
Principal investigator 1 Insmed, Inc. $75.00 04/26/2024 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1067603858
Principal investigator 1 Insmed, Inc. $75.00 04/26/2024 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1067603860
Principal investigator 1 Insmed, Inc. $600.00 04/26/2024 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1067609264
Principal investigator 1 Insmed, Inc. $75.00 04/26/2024 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1067609282
Principal investigator 1 Insmed, Inc. $1,965.36 04/26/2024 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1067609296
Principal investigator 1 Insmed, Inc. $1,407.55 04/26/2024 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1067609298
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $186.56 04/16/2024 Non-covered Recipient Entity
University Of Kansas Medical Center Department Of Neurology
Roll-over bronchiectasis No dispute reported 06/30/2026 1101071123
Principal investigator 1 Insmed, Inc. $11,481.39 04/12/2024 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1067593086
Principal investigator 1 Insmed, Inc. $11,481.39 04/12/2024 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1067603826
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $37,558.32 04/01/2024 Non-covered Recipient Entity
University Of Kansas Medical Center Department Of Neurology
Roll-over bronchiectasis No dispute reported 06/30/2026 1101071125
Principal investigator 1 Insmed, Inc. $53.40 02/29/2024 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 1067600976
Principal investigator 1 Insmed, Inc. $400.00 02/29/2024 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 1067600978
Principal investigator 1 Insmed, Inc. $154.86 02/29/2024 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1067609294
Principal investigator 1 Insmed, Inc. $400.00 02/21/2024 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 1067595596
Principal investigator 1 Boehringer Ingelheim International GmbH $1,675.54 02/01/2024 Non-covered Recipient Entity
University Of Kansas Medical Center Department Of Neurology
Roll-over bronchiectasis No dispute reported 06/30/2026 1101067943
Principal investigator 1 Insmed, Inc. $1,425.58 01/29/2024 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1067593100
Principal investigator 1 Insmed, Inc. $1,973.47 01/29/2024 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1067593102
Principal investigator 1 Insmed, Inc. $600.00 01/29/2024 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1067593104
Principal investigator 1 Insmed, Inc. $53.40 01/29/2024 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1067593106
Principal investigator 1 Insmed, Inc. $154.86 01/29/2024 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1067593110
Principal investigator 1 Insmed, Inc. $154.86 01/29/2024 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1067593112
Principal investigator 1 Insmed, Inc. $25.00 01/29/2024 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1067593120
Principal investigator 1 Insmed, Inc. $75.00 01/29/2024 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1067593122
Principal investigator 1 Insmed, Inc. $75.00 01/29/2024 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1067593124
Principal investigator 1 Insmed, Inc. $25.00 01/29/2024 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1067593126
Principal investigator 1 Insmed, Inc. $75.00 01/29/2024 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1067593128
Principal investigator 1 Insmed, Inc. $25.00 01/29/2024 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1067593130
Principal investigator 1 Insmed, Inc. $75.00 01/29/2024 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1067593132
Principal investigator 1 Insmed, Inc. $25.00 01/29/2024 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1067593134
Principal investigator 1 Insmed, Inc. $25.00 01/29/2024 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1067593136
Principal investigator 1 Insmed, Inc. $75.00 01/29/2024 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1067593138
Principal investigator 1 Insmed, Inc. $75.00 01/29/2024 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1067593152
Principal investigator 1 Insmed, Inc. $75.00 01/29/2024 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1067593154
Principal investigator 1 Insmed, Inc. $75.00 01/29/2024 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1067593156
Principal investigator 1 Insmed, Inc. $1,248.36 01/29/2024 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1067593158
Principal investigator 1 Insmed, Inc. $600.00 01/29/2024 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1067598488
Principal investigator 1 Insmed, Inc. $534.00 01/29/2024 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1067598490
Principal investigator 1 Insmed, Inc. $75.00 01/29/2024 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1067598492
Principal investigator 1 Insmed, Inc. $154.86 01/29/2024 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1067598494
Principal investigator 1 Insmed, Inc. $277.68 01/29/2024 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1067598496
Principal investigator 1 Insmed, Inc. $154.86 01/29/2024 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1067598498
Principal investigator 1 Insmed, Inc. $75.00 01/29/2024 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1067598502
Principal investigator 1 Insmed, Inc. $75.00 01/29/2024 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1067598504
Principal investigator 1 Insmed, Inc. $25.00 01/29/2024 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1067598506
Principal investigator 1 Insmed, Inc. $75.00 01/29/2024 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1067598508
Principal investigator 1 Insmed, Inc. $25.00 01/29/2024 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1067598510
Principal investigator 1 Insmed, Inc. $75.00 01/29/2024 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1067598512
Principal investigator 1 Insmed, Inc. $75.00 01/29/2024 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1067598514
Principal investigator 1 Insmed, Inc. $75.00 01/29/2024 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1067598516
Principal investigator 1 Insmed, Inc. $1,965.36 01/29/2024 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1067603838
Principal investigator 1 Insmed, Inc. $1,248.36 01/29/2024 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1067603840
Principal investigator 1 Insmed, Inc. $75.00 01/29/2024 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1067603842
Principal investigator 1 Insmed, Inc. $1,425.58 01/29/2024 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1067603844
Principal investigator 1 Insmed, Inc. $75.00 01/29/2024 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1067603846
Principal investigator 1 Insmed, Inc. $75.00 01/29/2024 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1067603848
Principal investigator 1 Insmed, Inc. $154.86 01/29/2024 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1067603850
Principal investigator 1 Insmed, Inc. $154.86 01/29/2024 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1067603852
Principal investigator 1 Insmed, Inc. $154.86 01/29/2024 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1067603854
Principal investigator 1 Insmed, Inc. $154.86 01/29/2024 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1067603856
Principal investigator 1 Insmed, Inc. $75.00 01/29/2024 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1067603862
Principal investigator 1 Insmed, Inc. $25.00 01/29/2024 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1067603864
Principal investigator 1 Insmed, Inc. $75.00 01/29/2024 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1067603866
Principal investigator 1 Insmed, Inc. $75.00 01/29/2024 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1067603868
Principal investigator 1 Insmed, Inc. $75.00 01/29/2024 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1067603870
Principal investigator 1 Insmed, Inc. $75.00 01/29/2024 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1067603872
Principal investigator 1 Insmed, Inc. $75.00 01/29/2024 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1067603874
Principal investigator 1 Insmed, Inc. $75.00 01/29/2024 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1067603876
Principal investigator 1 Insmed, Inc. $75.00 01/29/2024 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1067603878
Principal investigator 1 Insmed, Inc. $75.00 01/29/2024 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1067603880
Principal investigator 1 Insmed, Inc. $358.05 01/29/2024 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1067603882
Principal investigator 1 Insmed, Inc. $358.05 01/29/2024 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1067603884
Principal investigator 1 Insmed, Inc. $1,407.55 01/29/2024 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1067603886
Principal investigator 1 Insmed, Inc. $1,248.36 01/29/2024 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1067609268
Principal investigator 1 Insmed, Inc. $534.00 01/29/2024 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1067609272
Principal investigator 1 Insmed, Inc. $534.00 01/29/2024 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1067609274
Principal investigator 1 Insmed, Inc. $75.00 01/29/2024 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1067609276
Principal investigator 1 Insmed, Inc. $154.86 01/29/2024 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1067609278
Principal investigator 1 Insmed, Inc. $154.86 01/29/2024 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1067609280
Principal investigator 1 Insmed, Inc. $75.00 01/29/2024 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1067609284
Principal investigator 1 Insmed, Inc. $25.00 01/29/2024 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1067609286
Principal investigator 1 Insmed, Inc. $75.00 01/29/2024 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1067609288
Principal investigator 1 Insmed, Inc. $75.00 01/29/2024 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1067609290
Principal investigator 1 Insmed, Inc. $75.00 01/29/2024 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1067609292
Principal investigator 1 Insmed, Inc. $75.00 01/29/2024 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1067609300
Principal investigator 1 Insmed, Inc. $75.00 01/29/2024 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1067609302
Principal investigator 1 Insmed, Inc. $75.00 01/29/2024 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1067609304
Principal investigator 1 Insmed, Inc. $75.00 01/29/2024 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1067609306
Principal investigator 1 Insmed, Inc. $358.05 01/29/2024 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1067609308
Principal investigator 1 Insmed, Inc. $358.05 01/29/2024 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1067609310
Principal investigator 1 AstraZeneca UK Limited $79,361.59 01/26/2024 Non-covered Recipient Entity
THE UNIVERSITY OF KANSAS HEALTH SYSTEM
A Randomized, Double-Blind, Two-way Crossover Study to Assess the Effect of Hydrofluoroolefin (HFO) Propellant Metered Dose Inhaler (MDI) on Mucociliary Clearance Compared with Hydrofluoroalkane (HFA) Propellant MDI in Healthy Participants No dispute reported 06/30/2026 1110844238
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $37,955.40 01/19/2024 Non-covered Recipient Entity
University Of Kansas Medical Center Department Of Neurology
CatC inhibitor Phase II in bronchiectasis No dispute reported 06/30/2026 1101067411
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $2,173.80 01/01/2024 Non-covered Recipient Entity
University Of Kansas Medical Center Department Of Neurology
CatC inhibitor Phase II in bronchiectasis No dispute reported 06/30/2026 1101070713